Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center in Philadelphia, discussed the analysis of risk categories for patients when investigating axitinib (Inlyta) and pembrolizumab (Keytruda) over sunitinib (Sutent) in the updated analysis of KEYNOTE-426 presented at the 2020 ASCO Virtual Scientific Program.
One of the other analyses we did was look at risk categories: favorable risk vs poor and intermediate risk. In the poor and intermediate risk categories the benefit to overall survival, progression-free survival, and response rate remains and is highly statistically significant. In the favorable risk group, there was a benefit in terms of progression-free survival and response rate, but not overall survival. My commentary on that is that these patients do well. They are good risk or favorable risk. In this group of patients, it may just take longer for us to see any difference in overall survival since the vast majority are still alive, which is a good thing on this study.